RxDoctor Payments Data

Farzin Sehati, DO

Family Medicine · Forest Hills, NYNPI 1477636389

Payments from drug & device makers

$1,175in general payments, 2019–2025

Across 21 payments — averaging $55.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intra-sana Laboratories$394
  • Abbott$150
  • Pfizer$125
  • AstraZeneca$122
  • E.r. Squibb & Sons, L.L.C.$120
  • Ardelyx, Inc.$112
  • plus $152 from 5 others

What the payments were for

  • Food & beverage$1,175100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,175 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$79,217
Medicare patients
298
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$174,903
Droxidopa24$97,163
XareltoRivaroxaban43$25,340
EntrestoSacubitril/Valsartan18$12,717
RestasisCyclosporine19$11,751
MyrbetriqMirabegron31$8,949
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,921
Memantine Hcl179$8,369
Spiriva RespimatTiotropium Bromide12$7,100
Metoprolol Succinate313$4,928
Atorvastatin Calcium363$4,739
VascepaIcosapent Ethyl12$4,434
Levothyroxine Sodium333$4,005
Ezetimibe50$3,625
Midodrine Hcl50$3,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$174,903302 claims
GSKTrelegy Ellipta$25$8,92113 claims
Boehringer IngelheimSpiriva Respimat$18$7,10012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Forest Hills

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →